latest update:
[TrialBase DB]

trial summary · NCT07459634

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

A Phase 2, Multicenter, Open-Label, Single-Arm Study of Lurbinectedin in Combination With Durvalumab as First-line Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer Following Induction Treatment With Platinum Based Chemotherapy and Durvalumab

Trial record from the TrialBase DB dataset, status RECRUITING, condition Extensive-stage Small-cell Lung Cancer, sponsored by Jazz Pharmaceuticals. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07459634phase PHASE2enrollment 50start 2026-11-30

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.

Source record: https://clinicaltrials.gov/study/NCT07459634

Facts

registry idNCT07459634
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionExtensive-stage Small-cell Lung Cancer
sponsorJazz Pharmaceuticals
sponsor classINDUSTRY
enrollment50
start date2026-11-30
primary completion2028-01-31
completion2028-04-30
results postednot reported

Conditions

  • Extensive-stage Small-cell Lung Cancer

Interventions

  • Lurbinectedin
  • Durvalumab

Countries

  • United States

Intervention types: DRUG

Work with this record